CAMH develops potential new drug treatment for multiple sclerosis
A small molecule drug that aids in the neuroprotection of cells found to be effective in treating nerve damage and symptoms in models of MS
2023-12-08
(Press-News.org) December 8, 2023 (Toronto) – CAMH-led pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). The results have been published today in the journal Science Advances.
Expanding on Dr. Fang Liu’s earlier work that identified a novel drug target for the treatment of MS, she and her team have now created a small molecule compound that is effective in two different animal models of MS. This represents a key advancement that brings this MS research closer to the clinic to impact patient care.
MS is a progressive neurological disease that currently has no cure. It is associated with a wide-range of debilitating symptoms, including problems with coordination, cognition, muscle weakness and depression. For unknown reasons, it is more common in northern latitudes and more than twice as common in women.
It is known that MS damages myelin, a protective sheath that forms around nerves in the brain and spinal cord. As the myelin damage is triggered by inflammation in the immune system, up until now all current drug treatments for MS target the immune system.
In this study, CAMH Senior Scientist Dr. Fang Liu and her team treated MS in a completely different way—targeting the glutamate system. Study results showed that the newly synthesized lead compound not only reduced MS-like symptoms, it also may repair the damaged myelin in two different pre-clinical models of MS.
“Our compound had a stunning effect on rescuing myelin and motor function in the lab models, and I hope these effects will translate to the clinic to add to current treatments and bring new hope to patients with MS,” said Dr. Liu. “As with cancer chemotherapy drug cocktails, simultaneous targeting of the MS disease pathway at multiple points can have synergistic effects and result in better outcomes.”
Dr. Iain Greig, Reader in Medicinal Chemistry at the University of Aberdeen, alongside his team, are working to turn the molecules identified by Dr. Liu into advanced “drug-like” molecules suitable for continued development towards clinical use in patients. He added: “In all my years as a medicinal chemist, I have never seen a more promising starting point for a drug development project. It has been a huge pleasure to be involved in this program and I am looking forward to continuing to drive it towards to the clinic.”
Much of the funding for this novel treatment for MS, which Dr. Fang and her team have been investigating for over a decade, has come from the Multiple Sclerosis Society of Canada and the National Multiple Sclerosis Society USA’s Fast Forward commercial research program.
“We are pleased to have helped enable the early development of a novel neuroprotective strategy for MS, and look forward to seeing it progress through the critical next stages needed to determine its potential benefits for people living with MS,” said Walt Kostich, PhD, head of the National MS Society (USA)’s Fast Forward commercial research program.
Dr. Liu believes that the evidence of efficacy and tolerability generated in this study for the small molecule drug makes it a good candidate to be developed for human trials. The next steps in drug development will involve some further pre-clinical research, including investigating safety and stability of the compound. CAMH and the University of Aberdeen have already filed patent applications to protect this research and are actively seeking industry partners to further advance this work towards clinical trials over the next few years.
-30-
About The Centre for Addiction and Mental Health (CAMH)
CAMH is Canada's largest mental health and addiction teaching hospital and a world leading research centre in this field. CAMH combines clinical care, research, education, policy development and health promotion to help transform the lives of people affected by mental illness and addiction. CAMH is fully affiliated with the University of Toronto, and is a Pan American Health Organization/World Health Organization Collaborating Centre. For more information, please visit camh.ca or follow @CAMHnews on Twitter.
Media Contact:
CAMH Media Relations
media@camh.ca
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-12-08
An international team of experts undertaking fundamental research has developed a way of using polyethylene waste (PE) as a feedstock and converted it into valuable chemicals, via light-driven photocatalysis.
The University of Adelaide’s Professor Shizhang Qiao, Chair of Nanotechnology, and Director, Centre for Materials in Energy and Catalysis, at the School of Chemical Engineering, led the team which published their findings in the journal Science Advances.
“We have upcycled polyethylene plastic waste into ethylene and propionic acid with high selectivity using atomically dispersed metal catalysts,” said Professor Qiao.
“An oxidation-coupled ...
2023-12-08
SAN FRANCISCO—December 8, 2023—It only takes holding your breath for slightly too long to understand that too little oxygen is bad for you. But can you also have too much? Indeed, breathing air with a higher oxygen level than your body needs can cause health problems or even death.
But with scant research on the topic, scientists have known little about how the body senses too much oxygen. Now, a new study from Gladstone Institutes has greatly expanded the scientific body of knowledge about the mechanisms at play, and why it matters for health.
Their findings, reported in the journal Science Advances, explain how breathing air with different levels of ...
2023-12-08
TORONTO – A team of researchers based at the University of Toronto’s (U of T) Leslie Dan Faculty of Pharmacy has discovered a novel ionizable lipid nanoparticle that enables muscle-focused mRNA delivery while minimizing off-target delivery to other tissues. The team also showed that mRNA delivered by the lipid nanoparticles investigated in their study triggered potent cellular-level immune responses as a proof-of-concept melanoma cancer vaccine.
The study, led by Bowen Li, assistant professor, Leslie Dan Faculty of Pharmacy, U ...
2023-12-08
“In the United States, 288,300 new cases of prostate cancer are estimated for 2023 [...]”
BUFFALO, NY- December 8, 2023 – A new research perspective was published in Oncoscience (Volume 10) on November 30, 2023, entitled, “Evolving insights in blood-based liquid biopsies for prostate cancer interrogation.”
During the last decade, blood sampling of cancer patients aimed at analyzing the presence of cells, membrane-bound vesicles, or molecules released by primary tumors or metastatic growths emerged as an alternative to traditional tissue biopsies. The advent of this minimally invasive approach, known as blood-based liquid biopsy, ...
2023-12-08
The most durable, heat-resistant materials ever made could be hiding in plain sight.
The U.S. Department of Defense wants to know if minerals and rocks found on Earth and in space hold the secrets of next-generation high-temperature materials. To find out, the DOD awarded $6.25 million through its Multidisciplinary University Research Initiative, or MURI, to a team from the University of Virginia and Arizona State University. The group is led by UVA’s Elizabeth J. Opila, the Rolls-Royce Commonwealth Professor and chair of the Department of Materials Science and Engineering.
The ...
2023-12-08
Magnesium oxide is a promising material for capturing carbon dioxide directly from the atmosphere and injecting it deep underground to limit the effects of climate change. But making the method economical will require discovering the speed at which carbon dioxide is absorbed and how environmental conditions affect the chemical reactions involved.
Scientists at the Department of Energy’s Oak Ridge National Laboratory analyzed a set of magnesium oxide crystal samples exposed to the atmosphere for decades, and another for days to months, to gauge the reaction rates. They found that carbon ...
2023-12-08
A study looking at 15 years of HIV transmission and suppression in Uganda reveals how closing gender gaps in treatment could slash infection rates.
Providing more heterosexual men with easy access to HIV treatment and care could help to suppress the virus and rapidly cut transmission to their female partners, shows a new study published in Nature Microbiology.
The research, led by scientists from Imperial College London and the Rakai Health Sciences Program in Uganda, analysed 15 years of data from 2003-2018, during which the US President’s Emergency Plan For AIDS ...
2023-12-08
When Senior Scientist Jonathan Grimm came to Janelia 13 years ago, he didn’t know much about fluorescence or fluorescent dyes. But as an organic chemist who had been working in drug discovery at Merck, he certainly knew a thing or two about medicinal chemistry.
On a whim, Grimm and Janelia Senior Group Leader Luke Lavis decided to try using a mainstay medicinal chemistry reaction Grimm had picked up in the pharmaceutical industry to improve centuries-old dye chemistry. They thought this approach could allow access to completely new, previously inaccessible rhodamines – molecules Lavis had been working to make brighter and longer-lasting so they could be ...
2023-12-08
The Gerontological Society of America (GSA) — the country’s largest interdisciplinary organization devoted to the field of aging — is proud to acknowledge the work of 34 outstanding individuals through its prestigious awards program.
GSA salutes outstanding research, recognizes distinguished leadership in teaching and service, and fosters new ideas through a host of awards. Nominated by their peers, the recipients’ achievements serve as milestones in the history and development of ...
2023-12-08
Nuclear fusion, the process that powers the sun, is the ultimate source of energy for all life on Earth. On the sun, deuterium and tritium nuclei combine to produce an alpha particle (the nucleus of a helium atom) and a neutron. The dream is to do the same down here, on Earth, in a controlled manner.
It’s for good reason that harnessing fusion energy is one of the greatest scientific and technological challenges of the 21st century. Fusion requires the fuel to be heated to more than 100 million degrees (10 times hotter than the core of the sun). Practical fusion energy also requires that the burning fuel is kept at these hot temperatures long enough so that energy ...
LAST 30 PRESS RELEASES:
[Press-News.org] CAMH develops potential new drug treatment for multiple sclerosis
A small molecule drug that aids in the neuroprotection of cells found to be effective in treating nerve damage and symptoms in models of MS
